Skip to content
value.today
BioEclipse Therapeutics, Inc. logo

BioEclipse Therapeutics, Inc.

Formerly ConcentRx, Inc.

Total raised
$10 M
1 round on record
Latest round
$10 M
Jun 2019
First round on record
Jun 2019
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BioEclipse Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$10 MNo. 1$10 to $50 million

BioEclipse Therapeutics, Inc.: Raise no. 1, Jun 2019

Investors in this round

13 investors had bought by the notice of Oct 10, 2019: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $12 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$131,810
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Benjamin Carter · Executive Officer
  • Pamela Reilly Contag · Executive Officer, Director
  • Stephen Thau · Executive Officer
  • Biao He · Director
  • Catherine Sohn · Director
  • Elona Baum · Director
  • Gregory Schiffman · Director
  • Mark Frohlich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Venture.co Brokerage Services LLC (CRD 173924) · Burlington, VermontSold in all US states

Signed by Pamela Contag, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 10, 2019. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BioEclipse Therapeutics, Inc. reported no revenue for its most recent fiscal year (filed Apr 2022).

    SEC Form C/A · Apr 2022

  • Net loss for the same year: $4.39 million.

    SEC Form C/A · Apr 2022

  • BioEclipse Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2019).

    SEC Form D · Oct 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2019

In its own words

How the company describes itself to search engines on its website, word for word.

“BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of BioEclipse Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioEclipse Therapeutics, Inc.
NameRoleNamed in
Benjamin CarterExecutive officerOct 2019
Pamela Reilly ContagExecutive officerOct 2019
Stephen ThauExecutive officerOct 2019
Pamela ContagExecutive officerJun 2019
Biao HeDirectorOct 2019
Catherine SohnDirectorOct 2019
Elona BaumDirectorOct 2019
Gregory SchiffmanDirectorOct 2019
Mark FrohlichDirectorOct 2019
Pamela Reilly ContagDirectorOct 2019
Pamela ContagDirectorJun 2019